共 50 条
- [21] Phase II trial of high-dose bolus IL-2 in patients with metastatic melanoma (mm) who have previously failed biochernotherapy (BCT).JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 713S - 713SAgarwala, SSGooding, WD'Angelo, GKirkwood, JMStover, LLBaar, JShipe-Spotloe, J
- [22] Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 711 - 715Joseph, Richard W.Eckel-Passow, Jeanette E.Sharma, RuchiLiu, PingParker, AlexanderJakob, JohnBuchbinder, ElizabethBassett, Roland L.Davies, Michael A.Hwu, PatrickAtkins, Michael B.Sullivan, Ryan J.
- [23] A PHASE-I-II TRIAL OF OUTPATIENT HIGH-DOSE INTERLEUKIN-2 (IL-2)CLINICAL RESEARCH, 1987, 35 (06): : A864 - A864RICHARDS, JMRAMMING, KBARKER, EVOGELZANG, NJ
- [24] Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Jameson-Lee, MaxOtt, Patrick AlexanderLuke, Jason J.Postow, Michael A.Poklepovic, Andrew Stewart
- [25] NCI 8628-A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanomaCANCER RESEARCH, 2017, 77Tarhini, Ahmad A.Frankel, Paul H.Ruel, ChristopherErnstoff, Marc S.Kuzel, Timothy M.Logan, Theodore F.Khushalani, Nikhil I.Tawbi, Hussein A.Margolin, Kim A.Awasthi, SanjayMcDermott, David F.Chen, AliceLara, Primo N.Kirkwood, John M.
- [26] A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3385S - 3385SAlexandrescu, Doru T.Gonzales, ReneLewis, KarlSamlowski, WolframCranmer, LeeCatlett, JosephKirkwood, JohnWhitman, EricLawson, DavidBartels, P.Drake, TerryKeating, Anne
- [27] Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Wolchok, J. D.Thomas, L.Bondarenko, I. N.O'Day, S.Weber, J. S.Garbe, C.Francis, S.Ibrahim, R. A.Hoos, A.Robert, C.
- [28] Ipilimumab (MDX-010) in patients with unresectable stage III or IV malignant melanoma: efficacy and safety data from a phase I trialEJC SUPPLEMENTS, 2007, 5 (04): : 396 - 396Weber, J.Hersh, E.Yellin, M.Nichol, G.Urba, W.Powderly, J.O'Day, S.
- [29] AN OPEN-LABEL MULTICENTER PHASE II TRIAL OF AVISCUMINE IN PREVIOUSLY TREATED PATIENTS WITH UNRESECTABLE STAGE IV METASTATIC MELANOMAEUROPEAN JOURNAL OF CANCER, 2015, 51 : S7 - S7Uwe, TrefzerRalf, GutzmerTabea, WilhelmFlorian, SchenckKatharina, Kaehler C.Volkmar, JacobiKlaus, WitthohnHans, LentzenPeter, Mohr
- [30] A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4Buchbinder, Elizabeth I.Gunturi, AnasuyaPerritt, JessicaDutcher, JaniceAung, SandraKaufman, Howard L.Ernstoff, Marc S.Miletello, Girald P.Curti, Brendan D.Daniels, Gregory A.Patel, Sapna P.Kirkwood, John M.Hallmeyer, SigrunClark, Joseph I.Gonzalez, ReneRichart, John M.Lutzky, JoeMorse, Michael A.Sullivan, Ryan J.McDermott, David F.